Idorsia Ltd (IDRSF)
USD 1.0
(0.0%)
USD 1.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.46 Billion CHF | -6.16% |
| 2022 | 1.56 Billion CHF | 13.52% |
| 2021 | 1.37 Billion CHF | 62.23% |
| 2020 | 849.88 Million CHF | 1.19% |
| 2019 | 839.85 Million CHF | 12.11% |
| 2018 | 749.14 Million CHF | 35.62% |
| 2017 | 552.37 Million CHF | 35.67% |
| 2016 | 407.15 Million CHF | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 1.71 Billion CHF | -0.27% |
| 2024 Q1 | 1.71 Billion CHF | 16.92% |
| 2023 Q4 | 1.46 Billion CHF | -1.04% |
| 2023 Q2 | 1.56 Billion CHF | 0.65% |
| 2023 FY | 1.46 Billion CHF | -6.16% |
| 2023 Q1 | 1.55 Billion CHF | -0.42% |
| 2023 Q3 | 1.48 Billion CHF | -5.39% |
| 2022 Q2 | 1.39 Billion CHF | 1.31% |
| 2022 Q4 | 1.56 Billion CHF | -0.17% |
| 2022 FY | 1.56 Billion CHF | 13.52% |
| 2022 Q1 | 1.37 Billion CHF | -0.1% |
| 2022 Q3 | 1.56 Billion CHF | 12.36% |
| 2021 Q1 | 809.01 Million CHF | -4.81% |
| 2021 FY | 1.37 Billion CHF | 62.23% |
| 2021 Q4 | 1.37 Billion CHF | -4.98% |
| 2021 Q3 | 1.45 Billion CHF | 75.78% |
| 2021 Q2 | 825.46 Million CHF | 2.03% |
| 2020 Q4 | 849.88 Million CHF | 1.31% |
| 2020 FY | 849.88 Million CHF | 1.19% |
| 2020 Q1 | 832.17 Million CHF | -0.91% |
| 2020 Q3 | 838.88 Million CHF | 0.03% |
| 2020 Q2 | 838.63 Million CHF | 0.78% |
| 2019 Q2 | 825.39 Million CHF | 2.51% |
| 2019 Q4 | 839.85 Million CHF | 4.0% |
| 2019 FY | 839.85 Million CHF | 12.11% |
| 2019 Q3 | 807.56 Million CHF | -2.16% |
| 2019 Q1 | 805.18 Million CHF | 7.48% |
| 2018 Q3 | 757.59 Million CHF | 39.8% |
| 2018 FY | 749.14 Million CHF | 35.62% |
| 2018 Q2 | 541.93 Million CHF | 1.11% |
| 2018 Q1 | 535.96 Million CHF | -2.97% |
| 2018 Q4 | 749.14 Million CHF | -1.12% |
| 2017 Q1 | 412.04 Million CHF | 0.0% |
| 2017 FY | 552.37 Million CHF | 35.67% |
| 2017 Q4 | 552.37 Million CHF | 20.0% |
| 2017 Q3 | 460.32 Million CHF | 2.49% |
| 2017 Q2 | 449.13 Million CHF | 9.0% |
| 2016 FY | 407.15 Million CHF | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Bioxytran, Inc. | 3.24 Million USD | -45098.154% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | -2655.303% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -348293.142% |
| SQZ Biotechnologies Company | 50.03 Million USD | -2835.139% |
| Intellipharmaceutics International Inc. | 12 Million USD | -12130.348% |
| Evofem Biosciences, Inc. | 72.47 Million USD | -1926.623% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | -2388.753% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -38034.311% |
| Marizyme, Inc. | 26.67 Million USD | -5405.81% |
| Genus plc | 485 Million USD | -202.828% |
| Pharming Group N.V. | 244.07 Million USD | -501.752% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -72965.623% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -58267.351% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -38550.368% |
| ContraFect Corporation | 32.53 Million USD | -4414.814% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -38271.188% |
| IMV Inc. | 37.93 Million USD | -3771.885% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -12369.771% |
| ONE Bio Corp. | 27.49 Million USD | -5241.592% |
| RVL Pharmaceuticals plc | 77.41 Million USD | -1797.147% |
| Mesoblast Limited | 188.44 Million USD | -679.388% |
| MultiCell Technologies, Inc. | 1617.67 USD | -90791841.496% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | -1670.922% |
| Genscript Biotech Corporation | 1.32 Billion USD | -10.773% |
| Neon Bloom, Inc. | 1.22 Million USD | -119676.417% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -28440.692% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -15227.809% |
| Biomind Labs Inc. | 1.49 Million USD | -97904.954% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -16142.894% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -7880.66% |
| Skye Bioscience, Inc. | 14.07 Million USD | -10336.968% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -102330.71% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -25037.93% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -1033514.131% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -74028.505% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -15415.807% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -730182.026% |
| Accustem Sciences Inc. | 1.07 Million USD | -135987.929% |
| EV Biologics, Inc. | 2.11 Million USD | -69340.477% |
| Q BioMed Inc. | 8.13 Million USD | -17958.835% |
| GB Sciences, Inc. | 5.41 Million USD | -27010.264% |
| Alpha Cognition Inc. | 7.16 Million USD | -20399.097% |
| CSL Limited | 18.62 Billion USD | 92.113% |
| Agentix Corp. | 2.51 Million USD | -58401.566% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | -1137.101% |
| Enzolytics Inc. | 365.26 Million USD | -302.091% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | 67.39 Million USD | -2079.23% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -175011.239% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -25461.43% |
| argenx SE | 444.95 Million USD | -230.084% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | -1860.376% |
| HST Global, Inc. | 593.59 Thousand USD | -247327.783% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -85589.265% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -116539.308% |
| Halberd Corporation | 728.71 Thousand USD | -201447.373% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -5835.151% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -39972.259% |
| Zenith Capital Corp. | 27.56 Thousand USD | -5327311.223% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -12238.919% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -39230.307% |
| AVAX Technologies, Inc. | 3.99 Million USD | -36675.357% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -215622.775% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -54063.291% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -615315.623% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 7.86 Million USD | -18584.189% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -2194335.895% |
| Capstone Therapeutics Corp. | 50.26 Million USD | -2822.0% |
| Kadimastem Ltd | 3.5 Million USD | -41804.985% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 15.9 Million USD | -9134.484% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -315957.061% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -5353722.039% |
| LadRx Corporation | 2.2 Million USD | -66643.709% |
| Cell Source, Inc. | 15.8 Million USD | -9191.71% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -3285907.696% |
| Regen BioPharma, Inc. | 5.45 Million USD | -26811.274% |
| Regen BioPharma, Inc. | 5.45 Million USD | -26811.274% |
| Affymax, Inc. | 8.87 Million USD | -16456.352% |
| Mobile Lads Corp. | 1.31 Million USD | -111717.081% |
| Itoco Inc. | 1.65 Million USD | -88743.306% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -71489.933% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -24180.278% |
| International Stem Cell Corporation | 5.27 Million USD | -27732.367% |
| CytoDyn Inc. | 127.89 Million USD | -1048.384% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -3513653.918% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -93665.039% |
| Qrons Inc. | 1.48 Million USD | -98556.625% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -13197.198% |
| SYBLEU INC | 681.41 Thousand USD | -215439.475% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -181493.088% |
| Rebus Holdings, Inc. | 5.24 Million USD | -27918.199% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -23969.762% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -234590.457% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -31710.142% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | -3482.579% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -6496.515% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -72415.228% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -26711.135% |
| Neutra Corp. | 973.52 Thousand USD | -150764.946% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -4961.913% |
| PureTech Health plc | 125.58 Million USD | -1069.517% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -38991.433% |
| IXICO plc | 1.9 Million USD | -77188.859% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -7054.338% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -1321.465% |
| CSL Limited | 18.62 Billion USD | 92.113% |
| Cellectis S.A. | 249.36 Million USD | -488.971% |